Business Wire
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
📈
AI Sentiment
Highly Positive
8/10
Coya Therapeutics Inc. News
Latest updates and market news for COYA
1 news
Jan 1 - Jan 7, 2026
Page 1
Share this news page